No Detail Found!

Efectiveness of diferent tirofiban administration times in patients with no-reflow myocardial infarction during percutaneous coronary intervention

Author(s)
Chaosheng Mei Department of Cardiovascular Medicine, Hanyang Hospital affiliated to Wuhan University of Science and Technology, Wuhan, Hubei Province 430050, P.R. China.
Huiping Yu Department of Cardiovascular Medicine, Hanyang Hospital afiliated to Wuhan University of Science and Technology,54 Moshuihu Road, Wuhan, Hubei Province 430050,P.R. China
Abstract
Objective: To compare the efectiveness of diferent tirofiban administration time windows in patients with no-reflow myocardial infarction (MI) during percutaneous coronary intervention (PCI). Methods: This single centre retrospective observational study included patients with no-reflow MI, undergoing PCI at the Hanyang Hospital afiliated to Wuhan University of Science and Technology from March 2020 to May 2023. All patients were administered tirofiban. Patients who received tirofiban with postinterventional thrombolysis in myocardial infarction (TIMI) flow = 1 were grouped as Group-I, and patients who were directly given tirofiban through the guiding catheter without forward blood flow were grouped as Group-II. TIMI blood flow classification, levels of cardiac troponin T (cTnT) and creatine kinase isoenzyme MB (CK-MB), incidence of complications and major adverse cardiovascular events (MACE) in the two groups before and after the treatment were statistically analyzed. Results: A total of 156 patients were included in this study, including 79 patients in Group-I and 77 patients in GroupII. There was no significant diference in the baseline data between the two groups (P>0.05). After treatment, TIMI blood flow classification of the two groups improved and was significantly better in Group-I compared to Group-II (P0.05). The incidence of MACE in Group-I (3.80%) was lower than that in GroupII (12.99%) (P<0.05). Conclusions: Compared with the direct application of tirofiban, tirofiban given when TIMI Grade= 1 for patients with no-reflow MI during PCI can more efectively regulate the blood flow status of target vessels, reduce myocardial injury, and reduce the risk of MACE.
Publication Details
Page(s) 1969-1974
Published Journal: Pakistan Journal of Medical Sciences, Volume: 40, Issue: 9, Year: 2024

Request the full text from PASTIC

Keywords
Percutaneous Coronary Intervention, Tirofiban, time windows, No-reflow myocardial infarction
References
Salari N,Morddarvanjoghi F,Abdolmaleki A,Rasoulpoor S,Khaleghi AA,Hezarkhani LA .2023 .The global prevalence of myocardial infarction: a systematic review and meta-analysis. BMC Cardiovasc Disord, 10(1) : 206.
Nielsen TJ,Vestergaard M,Christensen B,Christensen KS,Larsen KK .2013 .Mental health status and risk of new cardiovascular events or death in patients with myocardial infarction: a populationbased cohort study. -003045, 10(8) : .
Guha A,Dey AK,Al-Kindi S,Miller PE,Ghosh AK,Banerjee A .2020 .Socio-Economic Burden of Myocardial Infarction Among Cancer Patients. Am J Cardiol, 11 : 16-22.
Jiao Y,Fu X,Liu Q,Zhang W. .2022 .The effects of AnisodamineTirofiban Combined Therapy in acute myocardial infarction treated with Percutaneous Coronary Intervention (PCI). Pak J Med Sci, 10(7) : 5410-1753.
Liu Y,Zhang L,Yang Y .2020 .Tirofiban hydrochloride sodium chloride injection combined with cardiovascular intervention in the treatment of Acute Myocardial Infarction. Pak J Med Sci, 10(2) : 1005-58.
Chen GX,Wang HN,Zou JL,Yuan XX .2020 .Effects of intracoronary injection of nicorandil and tirofiban on myocardial perfusion and short-term prognosis in elderly patients with acute STsegment elevation myocardial infarction after emergency PCI. World J Emerg Med, 03(3) : 8642-163.
Tang X,Li R,Ma L,Zhang T .2022 .Application of tirofiban in patients with acute myocardial infarction complicated with diabetes and undergoing emergency interventional therapy. Pak J Med Sci, 10(1) : 4545-178.
Kang SX,Meng XM,Li J .2022 .Effect of Tirofiban Injection on vascular endothelial function, cardiac function and inflammatory cytokines in patients with acute myocardial infarction after emergency Percutaneous Coronary Intervention. Pak J Med Sci, 10(1) : 4413-15.
Yang M,Huo X,Miao Z,Wang Y.,Platelet Glycoprotein Y. .2019 .IIb/IIIa Receptor Inhibitor Tirofiban in Acute Ischemic Stroke. Drugs, 10(5) : 515-529.
Denny O,Woodruff AE,Mills K,Chilbert MR,Pharmacol J Cardiovasc .2022 .Comparison of Ischemic and Bleeding Events Between Short-Duration Versus Long-Duration Tirofiban Regimens in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. , 10(1) : 56-61.
Ciliberti G,Compagnucci P,Urbinati A,Bianco F,Stronati G,Lattanzi S .2020 .Myocardial Infarction Without Obstructive Coronary Artery Disease (MINOCA): A Practical Guide for Clinicians. Curr Probl Cardiol, 10(3) : 100761.
Appleby MA,Michaels AD,Chen M,Michael CG .2000 .Importance of the TIMI frame count: implications for future trials. Curr Control Trials Cardiovasc Med, 10(1) : 31-34.
Fabris E,Ten Berg JM,Hermanides RS,Ottervanger JP,Dambrink JHE,Gosselink AM .2020 .NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: Insight from the On-TIME II trial. Am Heart J, 12 : 78-85.
Lei Z,Xiaoming Z,Yan H,Ming ZX,Med ZX .2015 .Analysis of the Best Timing for Applying Tirofiban in PCI Operation for the Patients with ST Segment Elevation Myocardial Infarction. , 10(1) : 382-387.
Zhang J,Ding G .2021 .Improved Cardiac Function and Attenuated Inflammatory Response by Additional Administration of Tirofiban during PCI for ST-Segment Elevation Myocardial Infarction Patients. Evid Based Complement Alternat Med, 10 : .
Guo YZ,Zhao ZW,Li SM,Chen LL .2021 .Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI. Sci Rep, 10(1) : 17144.
Zou X,Huang H. .2016 .The Infuence of Different Time Application of Tirofiban on the Immediate Targetangiography and Myocardial Injury in Patients with Acute ST segment Elevation Myocardial Infarction undergoing Percutaneous Coronary Intervention. Chinese Journal of Integrative Medicine on Cardio/ Cerebrovascular Disease, 22 : 1349-2606.
Zheng X .2015 .Comparative analysis of different application time of tirofiban in emergent interventional treatment of acute myocardial infarction on coronary blood flow and recent prognosis. China Practical Medical, 05 : 5547-25.
Zeng Q,Zhang LD,Wang W. .2020 .A meta-analysis of randomized controlled trials investigating tirofiban combined with conventional drugs by intracoronary administration for no-reflow prevention. Anatol J Cardiol, 10(1) : 7-16.
Sun B,Liu Z,Yin H,Wang T,Chen T,Yang S .2017 .Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes: A meta-analysis of randomized controlled trials. Medicine (Baltimore), 10(40) : .
Salama AM,Khalil WA,Al-Zaky M,Abdallah SH,Kandil NT,Abdelsabour A .2020 .-208a: a Good Diagnostic Marker and a Predictor of no-Reflow in STEMI Patients Undergoing Primary Percutaneuos Coronary Intervention. J Cardiovasc Transl Res, 10(6) : 988-995.
Wang G,Wang C,Huang Z,Sun S,Chen Y .2023 .Exosomal circ0020887 and circ-0009590 as novel biomarkers for the diagnosis and prediction of short-term adverse cardiovascular outcomes in STEMI patients. Open Med (Wars), 10(1) : 20230807.
Zhao Z,Qiu P,Lu H,Yin M,Liu X,Li F .2020 .Near-infrared -triggered release of tirofiban from nanocarriers for the inhibition of platelet integrin αIIbβ3 to decrease early-stage neointima formation. Nanoscale, 10(7) : 4676-4685.
0

Citations

0

Downloads

84

Views